FindTrial
Sign In

Clinical study for combined chemotherapy with arsenic trioxide for stage III osteosarcoma

Clinical study for combined chemotherapy with arsenic trioxide for stage III osteosarcoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032694
Enrollment
Unknown
Registered
2020-05-07
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma

Interventions

experimental group:N/A

Sponsors

The First Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with stage III osteosarcoma diagnosed by pathology admitted between 2020 and 2021 have at least one measurable focus; 2. The patients who received arsenic trioxide combined with cisplatin chemotherapy after disease progression or intolerability after treatment with at least one chemotherapy program (anthracycline drugs must be included); 3. Patients over 4 years old; 4. Patients who obtain the informed consent of their guardians and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other tumors; 2. Patients with heart, brain, kidney and other organ failure; 3. Patients who lost the follow-up data or lost a lot of follow-up data after treatment.

Design outcomes

Primary

MeasureTime frame
Objective response rate;Overall survival;Event-free survival;Progression-free survival;Adverse effect;—

Countries

China

Contacts

Public ContactJingnan Shen

The First Affiliated Hospital of Sun Yat-Sen University

shenjingnan@126.com+86 20-87755766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026